Professional
Added to YB: 2025-05-07
Pitch date: 2025-04-22
NVO [neutral]
Novo Nordisk A/S
-18.28%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 393.01
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
Polen Global Growth Portfolio Holding: Novo Nordisk A/S
NVO (holding update): Stock down 19% on disappointing CagriSema weight loss drug trial data in Q1, following similar December results. Despite concerns about next-gen drug's efficacy, still believe it has multi-billion dollar potential. Recent sell-off appears overdone.
Read full article (1 min)